CFC phaseout and advances in oral inhalers

Advances in Pharmacy

Volumn 3, Issue 2, 2005, Pages

  Gates, Brian J ^a   Neumiller, Joshua J ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,1,1 TRICHLOROETHANE; ADRENALIN; ATROPINE; BECLOMETASONE; BECLOMETASONE DIPROPIONATE; BITOLTEROL; BUDESONIDE; CARBON TETRACHLORIDE; CHLOROFLUOROCARBON; CROMOGLYCATE DISODIUM; DEXAMETHASONE; DICHLORODIFLUOROMETHANE; ERGOTAMINE TARTRATE; FLUNISOLIDE; FLUTICASONE; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL FUMARATE; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; METHYL BROMIDE; NEDOCROMIL; NEDOCROMIL SODIUM; NICOTINE; ORCIPRENALINE; PIRBUTEROL; PIRBUTEROL ACETATE; RESPIMAT; SALBUTAMOL; SALBUTAMOL SULFATE; SALMETEROL; SALMETEROL XINAFOATE; TIOTROPIUM BROMIDE; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

DATA BASE; DRUG DELIVERY SYSTEM; DRUG MANUFACTURE; DRUG MARKETING; INHALER; METERED DOSE INHALER; PRIORITY JOURNAL; REVIEW;

EID: 20444375060     PISSN: 15323862     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Holper P. The greenhouse effect. Commonwealth Scientific and Industrial Research Organisation (CSIRO) Atmospheric Research. Available at: www.dar.csiro.au/publications/ holper_2001b.html. Accessed on January 5, 2005.
2. Environmental Protection Agency. Ozone depletion glossary. Available at: www.epa.gov/ozone/defns.html#cfc. Accessed on January 3, 2005.
3. The Cancer Council Australia. All about skin cancer. Available at: www.cancer.org.au/content.cfm?randid=960742. Accessed on January 10, 2005.
4. Environmental Protection Agency. Ozone depletion rules Sc regulations. Available at: www.epa.gov/ozone/title6/phaseout/mdi/index.html. Accessed on January 7, 2005.
5. United Nations Environment Programme. The Montreal Protocol on Substances that Deplete the Ozone Layer. Available at: www.unep.org/ozone/montreal.shtml. Accessed on December 15, 2004.
6. CFC StarTec. Cooling appliances and the Clean Air Act. Available at: www.c-f-c.com/supportdocs/epa1.htm. Accessed on January 5, 2005.
7. National Asthma Council Australia. Asthma aerosol inhalers - the CFC-free transition. Available at: www.nationalasthma.org. au/resources/cfc/cfc_trans. html. Accessed on January 5, 2005.
8. United States Government Printing Office. Code of Federal Regulations. 21CFR2.125. April 14, 2004 edition. Available at: http://gpoaccess.gov.cfr/. Accessed on January 17, 2005.
9. Schering-Plough Corporation. Foradil Aerolizer. Available at: www.foradil.com. Accessed on January 8, 2005.
10. Boehringer Ingelheim Pharmaceuticals, Inc. Spiriva Handihaler. Available at: www.spiriva.com. Accessed on January 10, 2005.
11. GlaxoSmithKline. Advair Diskus. Available at: www.advair.com. Accessed on January 8, 2005.
12. GlaxoSmithKline. Serevent Diskus. Available at: www.serevent.com. Accessed on January 8, 2005.
13. AstraZeneca Pharmaceuticals LP. Pulmicort Turbuhaler film. Pulmicort International Portal. Available at: www.pulmicort.com/article/505686.aspx. Accessed on January 10, 2005.
14. Shafazand S, Colice G. Flunisolide HFA for the treatment of asthma: an old friend reformulated. Expert Opin Pharmacother. 2004;5:1163-1173.
15. Kos Pharmaceuticals, Inc. Products. Available at: www.kospharm.com/kos. asp?sec=2&page=14#. Accessed on January 15, 2005.
16. King Pharmaceuticals announces receipt of FDA approvable letter for Intal HFA. [press release]. Bristol, TN: King Pharmaceuticals, Inc.; October 30, 2003. Available at: www.kingpharm.com/news_details.asp?id_news=254. Accessed on January 16, 2005.
17. Boehringer Ingelheim Pharmaceuticals, Inc. Respimat Soft Mist. Available at: www.respimat.com. Accessed on January 12, 2005.
18. AstraZeneca Pharmaceuticals LP. Pulmicort Turbuhaler. Available at: www.twistclickinhale.com. Accessed on January 10, 2005.
19. Newhouse MT, Nantel NP, Chambers CB, et al. Clickhaler (a novel dry powder inhaler) provides similar bronchodilation to pressurized metered-dose inhaler, even at low flow rates. Chest. 1999;115:952-956.
20. 2 sympathomimetic. Clin Drug Invest. 2000;20(3):165-171.
21. Vitaris GmbH & Co. Novolizer. Available at: www.viatris-med.de/de/ patient/novolizer. Accessed on January 15, 2005. (Note: this site is in German and was translated using Google.)
22. Barry PW, O'Callaghan C. The influence of inhaler selection of efficacy of asthma therapies. Adv Drug Deliv Rev. 2003;55(7): 879-923.
23. Wolfe J, Kreitzer S, Chervinsky P, et al. Comparison of powder and aerosol formulations of salmeterol in the treatment of asthma. Ann Allergy Asthma Immunol. 2000;84(3):334-340.
24. Pauwels RA, Hargreave FE, Camus P, et al. A 1-year comparison of turbuhaler vs pressurized metered-dose inhaler in asthmatic patients. Chest. 1996;110:53-57.
25. Kilfeather SA, Ponitz HH, Beck E, et al. Improved delivery of ipratropium bromide/fenoterol from Respimat Soft Mist inhaler in patients with COPD. Respir Med. 2004;98:387-397.
26. Kunkel G, Magnussen H, Bergmann KC, et al. Respimat (a new soft mist inhaler) delivering fenoterol plus ipratropium bromide provides equivalent bronchodilation at half the cumulative dose compared with a conventional metered dose inhaler in asthmatic patients. Respiration. 2000;67:306-314.
27. Dahl R, Backer V, Ollgaard B, et al. Assessment of patient performance of the HandiHaler compared with the metered dose inhaler four weeks after instruction. Respir Med. 2003;97:1126-1133.
28. Meakin BJ, Dimond P. Bricanyl Turbuhaler, Serevent Accuhaler & Foradil Aerolizer: comparative drug delivery [abstract]. Thorax. 1996;51(suppl 3):A73.
29. Borgstrom L, Bondesson E, Moren F, et al. Lung deposition of budesonide inhaled via Turbuhaler - a comparison with terbutaline sulfate in normal subjects. Eur Respir J. 1994;7:69-73.
30. Newman SP, Moren F, Trofast E, et al. Terbutaline sulfate Turbuhaler-effect of inhaled flow-rate on drug deposition and efficacy. Int J Pharmaceut. 1991;74:209-213.
31. 2-agonists administered by a dry powder inhaler can be used in acute asthma. Respir Med. 1998;92:167-172.
32. Tonnesen F, Laursen LC, Evald T, et al. Bronchodilating effect of terbutaline powder in acute severe bronchial obstruction. Chest. 1994;105:697-700.
33. Vilsvik JS, Ringdal N, Albrektsen T, Holthe S. Comparison of the acceptability of the Ventolin metered-dose inhaler and the Bricanyl Turbuhaler. Ann Allergy. 1993;70:300-304.
34. Sheth K, Bernstein JA, Lincourt WR, et al. Patient perceptions of an inhaled asthma medication administered as an inhalation powder via the Diskus or as an inhalation aerosol via a metered-dose inhaler. Ann Allergy Asthma Immunol. 2003;91:55-60.
35. Schlaeppi M, Edwards K, Fuller RW, Sharma A. Patient perception of the Diskus inhaler: a comparison with the Turbuhaler inhaler. Br J Clin Pract. 1996;50:14-19.
36. van der Palen J, Klein JJ, Schildkamp AM. Comparison of a new multidose powder inhaler (Diskus)/Accuhaler) and the Turbuhaler regarding preference and ease of use. J Asthma. 1998;35:147-152.
37. Moore AC, Stone S. Meeting the needs of patients with COPD: patients' preference for the Diskus inhaler compared with the Handihaler. Int J Clin Pract. 2004;58:444-450.
38. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005;127:335-371.
39. FDA Talk Paper. FDA Publishes Final Rule on Chlorofluorocarbons in Metered Dose Inhalers. March 31, 2005. Available at: http://www.fda.gov/bbs/ topics/ANSWERS/2005/ANS01349.html. Accessed on April 25, 2005.